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Abstract: Streptococcus mutans is the main early colonizing cariogenic bacteria because it recognizes 31 
salivary pellicle receptors. The Antigen I/II of S. mutans is one of the most important adhesins in this 32 
process, is involved in the adhesion to the tooth surface and the bacterial co-aggregation in the early 33 
stage of biofilm formation. However, this protein has not been used as a target in a virtual strategy 34 
search for inhibitors. Based on the predicted binding affinities, drug-like properties and toxicity, 35 
molecules were selected and evaluated for their ability to reduce S. mutans adhesion. A virtual 36 
screening of 883,551 molecules was conducted, cytotoxicity analysis on fibroblast cells, S. mutans 37 
adhesion studies, scanning electron microscopy analysis for bacterial integrity and molecular 38 
dynamics simulation were also performed. We have found three molecules (ZI-187, ZI-939, ZI-906) 39 
without cytotoxic activity, which inhibited about 90% the adhesion of S. mutans to polystyrene 40 
microplates. Molecular dynamic simulation by 300 nanoseconds showed stability of the interaction 41 
between ZI-187 and Ag I/II (PDB: 3IPK). This work provides new molecules that targets Ag I/II and 42 
have the capacity to inhibit in vitro the S. mutans adhesion on polystyrene microplates.  43 
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1. Introduction 46 
In 2016 dental caries was classified as the most prevalent pathology in the world, affecting 2.4 47 
billion people [1,2]. This pathology is one of the oral diseases related to the oral microbiota alteration 48 
[3], characterized by perforations or structural damage of the teeth, called carious lesions [4]. There 49 
are three well-known risk factors for the development of caries: personal factors that are related to 50 
socioeconomic status i.e., dental insurance coverage, attitudes and knowledge about oral health and 51 
oral hygiene; oral environmental factors such as saliva, fluoride, chewing gum, pH, bacteria, calcium, 52 
phosphates, proteins and factors that directly contribute to the development of caries, like, the tooth, 53 
diet (consumption of sugars), bacterial biofilms and time [5].  54 
 55 
Oral microorganisms that cannot adhere to a surface are transported by salivary flow out of the 56 
mouth and into the digestive tract, but many oral bacteria possess mechanisms of adherence to solid 57 
surfaces (co-adhesion), such as coated teeth from salivary films, to squamous surfaces such as 58 
epithelial tissue or bacteria that are attached to the surface (co-aggregation) [6]. The streptococci 59 
compete for adhesion binding sites on the saliva-coated tooth surface and are able to produce 60 
antimicrobial compounds and S.mutans can become dominant in oral biofilms, leading to dental 61 
caries development [7]. This organism also produces glycosyltransferases (gtfs), multiple glucan-62 
binding proteins (Gbps), antigen I/II (also called SpaP, Pac, P1), and collagen-binding protein, these 63 
surface proteins coordinate the production of dental plaque [8]. The ability to form biofilms is one of 64 
the main S. mutans characteristics and it is a complex process of protein–bacterium interaction that 65 
begins with the attachment of a single cell, aggregation, microcolony formation until a mature biofilm 66 
[9]. Adherence to host tissues represents a critical step in the pathogenic process and is usually 67 
mediated by bacterial surface-exposed proteins in which S. mutans have mechanisms for adhesion 68 
sucrose-dependent (Gtfs essential) and sucrose-independent (Ag I/II essential) [10].   69 
 70 
In the absence of sucrose, S. mutans synthesizes several important adhesins such as antigen I/II 71 
(also called SpaP, Pac), which specifically binds to a glycoprotein called SAG (salivary agglutinin) 72 
[11,12], which has been proposed that participates as well in the tooth bacterial adhesion [13], and 73 
biofilm formation, this due to the fact that Ag I/II-deficient mutants formed 65% less biofilm than the 74 
wild-types [14] and  a decrease in its ability to promote the aggregation and invasion of the dentin 75 
of the collagen-dependent tooth [8,14]. Ag I/II virulence has been evaluated in a gnotobiotic rat model 76 
[15] and has been considered a promising target antigen for anticaries vaccines [16–19]. The overall 77 
structure of antigen I/II is conserved in all members of this protein family, this multidomain protein 78 
is composed of 1500–1566 amino acid residues (140- to 180-kDa) with a structure composed of 79 
alanine-rich variable V, proline-rich P, and C-terminal C domains [19–21]. The antigen I/II family of 80 
adhesins are cell wall-associated polypeptides that are widely distributed on the cell surface of many 81 
streptococci and is not only important for initial streptococcal adhesion to the host, but also for inter-82 
bacterial adhesion and “secondary” colonization; it also mediates interactions between S. mutans and 83 
Candida albicans [22,23]. Additionally, the presence of these protein on the cell surface determines the 84 
adherence of S. mutans to SAG but no difference in SAG-mediated adherence could be seen between 85 
type A and B strains [24]. Analysis of host and bacterial phenotype variation in adhesion of S.mutans 86 
has determinated that the host saliva phenotype and Ag I/II V-region plays a prominent role [25]. 87 
However, crystal structure information shows a possible model for AgI/II binding to SAG, where 88 
interactions occur at both the distal end through the A3VP1 region, and at a secondary adherence site 89 
mediated by the C-terminal domain [20].   90 
 91 
Numerous therapies for dental caries, have been proposed apart from the extensive use of 92 
fluoride, as xylitol [26,27], chlorhexidine [28,29], immunization [16,30], molecules derived from 93 
natural products [31], metal ions or oxidizing agents and even antibodies that specifically bind to S. 94 
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mutans targets (GtfB, GtfC, GtfD, Ag I/II) inhibiting the bacterial ability to develop biofilms [18,32], 95 
such strategies have been reported to target specific caries pathogens or to indiscriminately eliminate 96 
oral microbiota. However, the effectiveness of these methods is yet to be recognized, and safety 97 
concerns have been raised with regard to their negative impact in the ecology of the oral microbiota 98 
[33]. Other potential anticariogenic methods include the casein phosphopeptide-amorphous calcium 99 
phosphate nanocomplex (CPP-ACP), an agent that saturates saliva and biofilm, favoring the dental 100 
remineralization [34]; arginine which inhibit the growth of acidogenic or aciduric bacteria by raising 101 
the pH of the oral environment sugar substitutes [33] it has been proposed that the combined 102 
antimicrobial effect of arginine and fluoride have a potential synergistic effect in maintaining an eco-103 
friendly oral microbial equilibrium which helps prevent tooth decay, though the mechanism of 104 
arginine over the destabilization of biofilm is not yet clear [35,36]. These promising approaches may 105 
include the use of arginine as prebiotic and selected bacterial strains with arginine deiminase 106 
pathway (ADS+) as probiotic, like Streptococcus dentisani a bacterial isolated from dental plaque of 107 
caries-free individuals that has been shown to have several beneficial effects in vitro which could 108 
contribute to promote oral health, including an antimicrobial activity against oral pathogens by the 109 
production of bacteriocins and a pH buffering capacity through ammonia (Produced by arginine 110 
deiminase system) and the topic application of these probiotic could decrease the amount of dental 111 
plaque, but no differences were observed in the placebo group [37].   112 
 113 
Few of these treatments have been proven to confer selectivity against S. mutans or other 114 
cariogenic bacteria to prevent caries without disturbing the ecological balance between pathogens 115 
and commensal bacteria in the oral cavity. In recent decades, the virtual search for inhibitors based 116 
on structures has taken interest in drug discovery [38–40]; for oral microbiology the use of this 117 
strategy is relatively new, particularly in the cariogenic context, but several proteins have been 118 
proposed that could be used as inhibitory molecules [41]. Gtf-C has been used as a target on the 119 
search of molecules with affinity to this protein and for selectively inhibition of S. mutans biofilms 120 
formation mainly due to the ability to inhibit the synthesis of exopolysaccharides (EPS) in vitro, the 121 
biofilm formation and reduce in vivo the caries incidence and severity in a rat model [42,43]. Although 122 
the Ag I/II adhesin has been reported to play an important in the early stages of S. mutans biofilm 123 
development, participating in adhesion and co-aggregation with other bacteria and fungi such as C. 124 
albicans, there are no reports of computational studies that use this protein as target, therefore, the 125 
aim of this work is to identify in silico molecules with inhibitory effect on S. mutans Ag I/II, , which 126 
have no cytotoxic activity on human cells. 127 
2. Results and Discussion 128 
2.1. Structure based virtual Screening 129 
2.1.1. Target proteins selection  130 
The Ag I/II of S. mutans play an essential role in the etiology and pathogenesis of dental caries. 131 
Therefore, the discovery of inhibitors of Ag I/II may facilitate the development of drugs that prevent 132 
dental caries. Ag I/II is one of the cell wall-anchored adhesins that mediates attachment of S. mutans 133 
to tooth surfaces, recognize salivary glycoproteins, and are also involved in biofilm formation. 134 
Finding small-molecule that bind to the Ag I/II may interfere with the function of these adhesine. To 135 
address this, we selected a sequence of the S. mutans Ag I/II adhesin and we found a crystal structure 136 
from different regions of AgI/II, which corresponds to the A3VP1 region (PDB: 3IPK) [21], C-terminal 137 
domain, region V (PDB: 1JMM) [44] and two from the C-terminal domain (PDB: 3QE5) [20] and (PDB: 138 
3OPU) [45] (Figure S1). According to sequence similarity and coverage results (Table S1), the crystals 139 
structures of the proteins 3IPK and 3QE5 were selected, due to their role in S. mutans adhesion to the 140 
tooth, through their SAG binding [21] (Figure 1). 141 




Figure 1. Crystals structures from the S. mutans Ag I/II protein (A). Model of S. mutans Ag I/II structure and 144 
predicted binding with human SAG (taken from [21]). (B) Crystal structure of A3VP1 protein from Ag I/II (3IPK) 145 
[21]. (C). Crystal structure C-domain protein from the Ag I/II (3QE5) [20]. (D). Schematic representation of the 146 
Ag I/II protein sequence (1566 aa) and the description of the aa residues that constitute the crystals structures of 147 
the protein regions: 1- Region V ( PDB: 1JMM) [44]; 2- C-terminal domain [45]; 3- A3VP1 region (PDB: 3IPK) [21] 148 
and 4- the C-terminal region (PDB: 3QE5) [20]. 149 
Sequence and structural similarity analysis of 3IPK and 3QE5 was performed in order to identify 150 
other similar proteins in another organism. However, no significant homologies were found, which 151 
could be an indication that these molecules would not affect human (Table S2) or bacterial proteins 152 
important for the ecological balance of the oral microbiota, but a lack of overall protein similarity 153 
may not exclude local similarities in the properties of the ligand binding pockets i.e. two unrelated 154 
proteins may share pockets with the ability to bind a common compound.  On the other hand, we 155 
have found sequence homologies with proteins from 23 bacterial species, which are mostly normal 156 
inhabitants of the oral cavity, gastrointestinal and genitourinary tracts, but are associated with 157 
different pathologies (Table S3, S4). Regarding the structural homologies for 3IPK and 3QE5 proteins, 158 
there were no similarities with any human or bacterial proteins, only with S. mutans Ag I/II regions, 159 
A3VP1 region (PDB: 3ioxA) [21] and N-terminal and C-terminal interaction complex (PDB: 4tshA) 160 
(Table S5) [46].  161 
A fundamental step for the search of molecules based on virtual structures, is the pocket 162 
selection, these sites must have typical characteristics such as concave, have a variety of hydrogen 163 
bridge donors and acceptors and hydrophobic characteristics [47], otherwise, false negatives may 164 
occur when selecting molecules for in vitro assays, since errors may occur when there are no binding 165 
sites in the protein or when homology models are used, causing for example, small-volume pockets 166 
to be selected that will generate incorrect unions or conformations [48]. For that reason, in this study, 167 
two multiservers or specific programs were used for protein ligand binding site prediction, which 168 
have different selection algorithms, the MetaPocket uses a consensus method based on the predicted 169 
sites of four free access programs LIGSITEcs , PASS, Q-SiteFinder and SURFNET, which are 170 
combined to improve the success rate of the prediction and which is based on the geometry and 171 
surface of the proteins [49], unlike the COACH that uses the consensus of two methods, one based 172 
on the comparison of specific binding substructures (TM-SITE) and the other on the alignment of the 173 
sequence profile (S-SITE), for predictions of binding sites based on known proteins [50] (Figure S2).  174 
2.1.2. Molecules selection 175 
Ten molecules were arbitrarily selected according to their molecular docking score and ten 176 
according to the number of pockets interaction. The lowest docking score indicates high affinity 177 
between the molecule and the ligand. Therefore, molecules that interacted in several binding sites 178 
were selected, because those could have a greater coating of the target protein allowing the inhibition 179 
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of the two important regions of Ag I/II involved in its adhesin function. Interestingly, we found 180 
molecules that binding to more than one site of the same protein domain, A3VP1 in the V region and 181 
C-terminal region, this could have been possible because these proteins have several conserved 182 
regions in their structure, in PDB: 3IPK the A region typically consists of 3–4 alanine rich repeats (82 183 
residues each) with 23–30% alanine content, the P region has 3–4 proline-rich repeats (39 residues 184 
each) with ∼35% proline content and in PDB: 3QE5 the sequence have a high proline content that 185 
forms a repetitive proline- rich region [20,21,51]. In addition, A3VP1 and the C-terminal fragments 186 
has multiple binding sites and similar affinities for binding to SAG, which support the simple model 187 
proposed about the high-affinity binding of AgI/II with SAG occurs via the apical fishhook-like 188 
structure observed within A3VP1, and an additional interaction occurring within the C- terminal 189 
region[21].   190 
 191 
Table 1. Energy interaction data obtained from recoupling using Autodock Vina with an exhaustiveness 192 
of twenty for the 3IPK and 3QE5 proteins with the selected molecules, molecule libraries and number of pockets 193 
in which each molecule interacted. The molecule highlighted in black was the only one that interacted with high 194 
affinity in different sites in both 3IPK and 3QE5 proteins. COA: COACH program. MET: Metapocket 2.0 195 
program. Values highlighted in light blue represent the lowest interaction energy values. 196 
NUMBER OF 
MOLECULES 
INTERACTION POCKETS   MOLECULES LIBRARY 
3IPK 3QE5 
P1 P2 P3 P1 P2 P3 
COACH MET COACH MET COACH MET COACH MET COACH MET COACH MET 
Not applicable 
ZINC68568370   NAT -12,8 -12,8 -7,5 -9 -9,4 -10,9 -8,5 -8,8 -8,1 -8,9 -7,1 -7,7 
ZINC70669788 NAT -11,4 -12,8 -7,5 -8,4 -8,7 -10,1 -7,9 -8,7 -7,7 -7,6 -7,6 -6,5 
ZINC70669789 NAT -11,5 -12,7 -7,3 -8,3 -8,8 -9,8 -8,1 -9 -7,9 -7,8 -7,8 -6,3 
ZINC34257514 NAT -12,6 -12,6 -6,7 -8,8 -7,7 -9,8 -6,9 -8,7 -6,8 -7,6 -6,7 -7,6 
ZINC04817561   NAT -10,3 -12,4 -10,1 -8,3 -8,6 -12,4 -7,2 -9,2 -7,1 -7,9 -7,2 -7 
ZINC67912808 NAT -12,3 -12,5 -8,2 -8,8 -8,4 -9,1 -7,6 -9,5 -7,6 -8,1 -7,1 -6,8 
ZINC70686498 NAT -12,2 -12,2 -7,8 -8,2 -8 -9,9 -7,4 -8,1 -7,3 -9,6 -6,6 -7,1 
ZINC04015296 NAT -11,7 -11,6 -8,4 -9,8 -9 -11,7 -9,3 -11,4 -7,5 -9,3 -7,4 -9,8 
ZINC08594547 LRG -11,6 -11,7 -7,7 -8,5 -8,1 -11,4 -7,6 -8,6 -7,1 -8,2 -6,5 -8,3 
12 ZINC00970517 SM -9,4 -9,4 -9 -8,2 -7 -9 -6,7 -7,7 -6,3 -7,5 -5,9 -7,3 
12 ZINC01033612 SM -9,3 -9,5 -8,7 -7,7 -7,3 -9,4 -7,4 -7,8 -7 -8,1 -7,4 -7,5 
12 ZINC08647964 SM -9,7 -9,8 -9,4 -7,9 -7,4 -10,4 -6,9 -8,4 -6,8 -8,7 -6,2 -7,5 
12 ZINC12369546 SM -9,5 -10 -9,1 -8,3 -7,5 -9,8 -7,9 -8,3 -6,7 -7,8 -6,8 -8,5 
12 ZINC19924906 SM -11,1 -11 -7,2 -8,2 -7,1 -9,2 -6,9 -8,3 -6,7 -7,5 -6,8 -7,5 
12 ZINC03120327 SM -9,6 -9,7 -10,1 -7,9 -7,1 -10,1 -6,7 -8 -7,1 -8 -6,9 -8,5 
12 ZINC19835160 SM -10,3 -9,5 -6,9 -8,7 -7,7 -9,7 -6,6 -8,4 -6,7 -8 -5,8 -6,9 
12 ZINC19835187 SM -10,7 -10,7 -9,2 -8,8 -8,5 -10,3 -8,1 -8,7 -7,5 -8,4 -6,9 -8,8 
12 ZINC19924939 SM -10,4 -10,4 -9 -8,9 -7,2 -8,1 -7,6 -7,5 -7,1 -8 -6,4 -7,9 
12 ZINC59608258 SM -9,4 -10,1 -7,8 -7,9 -7,2 -8,9 -6,8 -7,7 -6,1 -7,6 -6,3 -6,7 
 197 
Finally, nineteen molecules were obtained, because the ZINC19924906 molecule from the library 198 
"Small" was selected according to the best docking score and the interaction with different ligand 199 
sites in the domains. The molecules with the lowest docking score were from the library "Natural", 200 
such as ZINC68568370 with a docking score of -12.8. The molecules that had a higher number of 201 
binding sites were found from the library "Small" and were coupled to the 12 pockets used for 202 
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docking, which means that they have affinity for several pockets in both the PDB domain: 3IPK and 203 
PDB: 3QE5 (Table 1). 204 
Molecules that comply the standard physical-chemical parameters and pharmacokinetic profiles 205 
are presented in table S6. However, one molecule was discarded for having an LD50 = 10mg / kg (C-206 
II) (Figure S3) and fourteen for having the probability of presenting hepatotoxicity, carcinogenicity, 207 
immunotoxicity and/or mutagenicity characteristics (Figure S4). Finally, we obtained four molecules 208 
ZINC19835187 (ZI-187), ZINC19924939 (ZI-939), ZINC19924906 (ZI-906) and ZINC70686498 (ZI-498) 209 
(Figure 2) which did not present any probability of cytotoxic characteristics, as well as the 210 
Chlorhexidine (Figure S4). 211 
           212 
A           B 213 
             214 
  C        D 215 
      216 
 217 
 218 
Figure 2. Molecules structures selected by in silico analysis, which have affinity for Ag I/II and 219 
inhibitory potential of S. mutans adhesion. A- ZI-187; B- ZI-939; C- ZI-906; D- ZI-498. 220 
Three molecules belonging to the small library (ZI-187, ZI-939, ZI-906) were selected, molecules 221 
from this library, basically, contain drug-like properties such as molecular weight (<500 Da), 222 
hydrogen bond acceptors (HBA) (<10), hydrogen bond donors (HBD) (<5), partition coefficient AlogP 223 
(<5). Some structural fragments of these molecules are evident, such as the case of 9h-fluorene and 224 
Piperazine (Figure 2). Thiazol was common for ZI-187 and ZI-906 (Figure 2A, 2C). Fluorene or 9H-225 
fluorene is a polycyclic aromatic hydrocarbon insoluble in water and many of its derivatives have 226 
attracted wide attention as basic building blocks for the production of pharmaceuticals, drugs, 227 
lubricating materials, and thermosetting plastics [52]. Piperazine on the other hand, is an organic 228 
compound and heterocyclic amine, this has proven to be of great significance in the rational 229 
development of drugs and its found in well-known drugs with various therapeutic uses, such as 230 
antipsychotic, antihistamine, antianginal, antidepressant, anticancer, antiviral, cardio protectors, 231 
anti-inflammatory, and imaging agents [53]. However, the properties of these fragments alone change 232 
considerably when they are part of other chemical molecules. Finally, the molecule ZI-498 belongs to the library 233 
of natural compounds and presents structural fragments different from the molecules previously described, ZI-234 
498 include naphthalene, piperidine, and benzene (Figure 2D). 235 
 236 
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The presence of one or two hydrogen bridges was confirmed (Table S7) using the interaction 239 
complexes in the pockets established by the two predictors between the selected molecules and the 240 
3IPK and 3QE5 proteins. This finding could indicate that the interaction between each molecules ZI-241 
187, ZI-939 and ZI-906 with both proteins, would have very stable couplings, resulting in a possible 242 
inhibition of the S. mutans adhesion, since it has been shown that hydrogen bridges regulate and 243 
facilitate molecular interactions [54–58].  244 
 245 


























Figure 3. Comparison of the interactions of three molecules with A3VP1 region (PDB: 3IPK) and 272 
C-terminal region (PDB: 3QE5) from Ag I/II of S. mutans. Hydrophobicity in surface form is shown 273 
for the A3VP1 region interacting with (A) ZI-187, (E) ZI-906 and (I) ZI-939 and C-terminal region 274 
interacting with (C) ZI-187, (G) ZI-906 and (K) ZI-939, where the color scale corresponds to that blue 275 
is very hydrophilic and red is very hydrophobic. Molecular interactions (to 3 Angstrom radius from 276 
the molecules) between residues from A3VP1 region with (B) ZI-187, (F) ZI-906 and (J) ZI-939 and 277 














































































































































Additionally, the hydrophobicity analysis of the two Ag I/II domains (PDB: 3IPK and PDB: 281 
3QE5), showed that the three molecules ZI-187, ZI-906 and ZI-939 have a similar interaction with both 282 
domains, in which the interaction site is characterized by one hydrophobic and hydrophilic regions 283 
(figure 3). The 9h-fluorene fragment, which is present in the three molecules, interacts with the same 284 
residues from PDB: 3IPK domain, Thr586 - Val587 - Phe656 - Asp760 - Trp816, which are 285 
hydrophobic, with the exception of Asp760 (Figure 3B, 3F , 3J). However, the interaction of the 9h 286 
fluorene fragment with PDB domain: 3QE5 is similar for the molecule ZI-187 and ZI-906, which 287 
interact with the residues Val1340 - Gly1354 - Gln1355 - Arg1465 - Thr1470 - Phe1471 (Figure 3D, 3H), 288 
most of them hydrophobic. The molecule ZI-939 also shows interaction with different hydrophobic 289 
residues, but different Ile1157 - Tyr1322 - Ala1323 (Figure 3L). On the other hand, the fragments that 290 
are different within the three molecules, interact mostly with hydrophilic residues; we found that for 291 
the PDB: 3IPK domain the molecules interact in the same way with the residues Asn699 - Glu701 - 292 
Ser704 - Ile815, and the interactions with PDB domain: 3QE5 are also characterized by hydrophilic 293 
residues. Only the molecules ZI-187 and ZI-906 showed interactions with common residues, such as 294 
Lys1338 - Asp1353 - Asn1473 - Ser1486 (Figure 3D, 3H), different from those of ZI -939 which were 295 
Lys1023-Gln1024-Leu1113-Gly1321 (Figure 3L). 296 
Finally, a descriptive analysis about water solubility of the molecules was conducted using a 297 
consensus from 3 methods resulting in a low aqueous solubility of the molecules , but this parameter 298 
was no used as a selection criteria for molecule selection (Table S8). 299 
 300 
2.2 In vitro assays  301 
2.2.1 Cytotoxicity and antimicrobial assays 302 
It was found that molecules at concentrations of 100 µM have no effect on periodontal ligament 303 
fibroblast cells growth and the cells treated with molecules ZI-187 (P= 0.7372), ZI-939 (P= 0.8) and 304 
ZI-906 (P= 0.7964) (Figure 4). However, cells treated with each molecules showed changes in size and 305 
granularity. Therefore, it is important to analyze other human cell lines and add complementary 306 
analysis such as incorporation of DIOC6 for the mitochondrial membrane potential measurement 307 
[59] or apoptosis tests as Annexin V [60]. In addition, for antimicrobial assays molecules at 308 
concentrations of 1000 - 100 - 10 µM co-cultured experiments with S. mutans LT-11 or C. albicans - 309 
NCPF 3179, did not affect their growth (P= <0.001) (Figure S5 and S6, respectively). 310 
 311 
 312 
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Figure 4. Cytotoxicity evaluation of compounds ZI-187 (P= 0.7372), ZI-939 (P= 0.8) and ZI-906 (P= 0.7964) (100 313 
µM) on periodontal ligament fibroblast cells (PLF), by laminar flow cytometry analysis with Propidium Iodide. 314 
 315 
2.2.2 Adhesion assays 316 
The S. mutans LT11 three hours adhesion inhibition test with each molecule selected (ZI-187, ZI-939, 317 
ZI-906) inhibited the surface adhesion to a polystyrene microwell plate. The three molecules showed 318 
an adhesion inhibition greater than 90% at a concentration of 200 µM, 95.9% (SEM = 0.6 ) with ZI-187, 319 
96.9% (SEM = 0.3) with ZI-906 and 93% (SEM = 0.7) with ZI-939 (Figure 5). This inhibition of adhesion 320 
is maintained above 90% at a concentration of 100 µm only with the molecule ZI-187 (95.0%, SEM = 321 
0.6) (Figure 5A) and for the molecules ZI-906 and ZI-939 the inhibition capacity decreases to 83.1% 322 
(SEM = 5.5) and 81.7% (SEM = 1.8) with ZI-906 and ZI-939 (Figure 5B, 5C), respectively. Interestingly, 323 
the molecules ZI-187 and ZI-906 showed significant differences (P-Value <0,001) in comparison to S. 324 
mutans Ag I/II deficient (S. mutans SpaP-). Up to a concentration of 50 µM, the adhesion inhibition 325 
percentages were 81.6% (SEM = 2.1) for ZI-187 and 74.5% (SEM = 5.9) for ZI-906, but there was no 326 
statistically significant difference for adhesion inhibition of 27.9% (SEM = 3.3) with ZI-939. 327 
Additionally, with these results the IC50 (The half maximal inhibitory concentration) was calculated, 328 
finding that the IC50 for ZI-187 was 27.6 µM (95% CI = 17,4 - 44,5) (Figure 5-A), IC50 of 28.3 µM (95% 329 




Figure 5. Surface adhesion of S. mutans - LT11 to a polystyrene microwell plate treated with 334 





























































DMSO (10%): 84.8 %  (SEM = 3.9)
CHX (0.2%). :  38.6 %  (SEM = 2.0)
200 µM         :    4.1 %  (SEM = 0.6)
100 µM         :    5.0 % (SEM = 0.6)
  50 µM         :  18.4 %  (SEM = 2.1)
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DMSO (10%): 84.8 %  (SEM = 3.9)
CHX (0,2%).  :  38.6 % (SEM = 2.0) 
200 µM           :    7.0 %  (SEM = 0.7)
100 µM           :  18.3 % (SEM = 1.8)
  50 µM           : 72.1 %  (SEM = 3.3)
  25 µM           : 83.0 %  (SEM = 3.3) 
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These findings show the importance of the molecules fragments (9h-fluorene and Piperazine) in 336 
the adhesion inhibition, because it has been shown that bacteria have mechanisms that modify the 337 
surfaces to increase hydrophobicity and be able to adhere [61,62]. For this study, it was found that 338 
the 9h fluorene fragment is very important for adhesion inhibition of S. mutans, since the three 339 
molecules contain this fragment and interact with hydrophobic parts of the residues and additionally 340 
the other fragments such as 2,3 Dihydrobenzofuran in ZI-187, could be important for inhibition 341 
capacity. 342 
 343 
Additionally, an agglutination phenomenon was observed when molecules with the bacteria 344 
was mixed, only at concentrations where the inhibition was affected (Figure S7). ZI-187 was the only 345 
molecule that maintained adhesion inhibition above 90% at a concentration of 100 µM, hence this was 346 
selected for scanning electron microscopy. Reduction of adherent bacteria was evident, and we did 347 
not observe morphological changes in S. mutans following treatment with ZI-187, bacteria had intact 348 
cell structure and round shapes with smooth edges (Figure 6). 349 
 350 




Figure 6. Scanning electron microscopy of S. mutans-LT11 surface adhesion to a polystyrene 355 
microwell plate. Without treatment at 7,000x (A) and 19,000x (B); and treated with 100 µM of 356 
molecule ZI-187, at of 4,000x (C) and 11,000x (D). 357 
There are multiple chemical strategies that could limit the development of dental biofilm, 358 
however, most of them can have side effects on teeth, soft tissues or killing oral microbiota, which 359 
show the need for specific therapies for cariogenic bacteria. Several studies have focused on blocking 360 
two important mechanisms for S. mutans biofilm development, such as avoiding sucrose-dependent 361 
or sucrose-independent adhesion and interference of cellular signaling “Quorum sensing” [10]. This 362 
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mainly at blocking sortase A, a transpeptidase involved at the anchoring of cell surface proteins, 364 
including Ag I/II, through the LPXTG motif. It has been found that several molecules can reduce 365 
biofilm formation, through the inhibition of the sortase A [63,64], such is the case of the natural phenol 366 
curcumin, (Curcuma longa) with which it has been reported inhibition S. mutans sortase A activity 367 
with IC50: 10 µM and a MIC of 175 µM [65]. However, despite the multiple benefits of this molecule, 368 
some toxic effects have also been evidenced related to the high doses as result from its use as a 369 
supplement in the diet [40,41]. Another natural product is named Morin, it has an inhibitory effect 370 
against S. mutans SrtA with IC50: 27.2 µM [66,67]. Morin other natural product, has an inhibitory 371 
effect against S. mutans SrtA with IC50: 27.2 µM [68], similar to the IC50 obtained with our molecules 372 
ZI-187 and ZI-939 (IC50: 27,6 y 28,3 µM, respectively). However, the antimicrobial activity of Morin 373 
has also been reported against S. mutans [69], differently from the molecules found in this study that 374 
did not present cytotoxic or antimicrobial activities. 375 
2.2.3 Molecular dynamics simulations (MD) 376 
Using molecular dynamics simulation, we have found that the complex 3IPK/ZI-187 attained a 377 
high stability after 300ns, during this time the 3IPK protein did not have strong changes when it was 378 
coupled with ZI-187 (Figure 7A), which could indicate that the interacting molecule moves on the 379 
pocket, but not drastically, this means that it does not destabilize the complex; in agreement with the 380 
RMSD result, no significant fluctuation of amino acid residues was observed, however, between 381 
residues 550-600 and 800-850, some differences were showed between the APO protein for 3IPK 382 
(black) and the complex (red) (Figure 7B), which could be due to the specific 3IPK residues that 383 
interact with ZI-187, since different types of interactions of ZI-187 with residues Leu 553 - Asp 554 - 384 
Thr 586 - Val 587 and Lys 811 - Lys 812 - Asn 814 - Ile 815 - Trp 816 were identified (Figure S6). In 385 
addition, 1 and 2 H-bonds were observed between the complex during the simulation time (Figure 386 
7C) and a constant protein structure compactness in the complex (Figure 7D), these two parameters 387 
would support the stability of the interaction between ZI-187 and 3IPK, giving a possible explanation 388 
for the molecule's ability to inhibit the adhesion of S. mutans. 389 
 390 
A            B 391 
  392 
C            D 393 
  394 
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Figure 7. Molecular dynamics simulations analysis. RMSD (Root Mean Square Deviation) (A) - 395 
RMSF (Root Mean Square Deviation) (B), hydrogen bonds (C) and Radius of gyration (D) calculated 396 
for ZI-187/3IPK complex. 397 
 398 
Finally, the present work allowed to establish a virtual search strategy and selection pipeline for 399 
adhesion inhibitory molecules of a cariogenic bacteria but that could be applicable to any pathogen. 400 
This study, to the best of our knowledge, is the first report that uses the S. mutans Ag I/II as a target, 401 
since the previous studies were mainly performed on Gtfs or sortase A proteins. Three molecules 402 
were selected ZI-187, ZI-939 and ZI-906, without showing any cytotoxic effect on periodontal 403 
ligament fibroblasts or antimicrobial activity on S. mutans or C. albicans. However, it is suggested to 404 
perform assays in other different human cell lines, as well as on other microorganisms of oral cavity 405 
importance to evaluate in a much wider range other possible effects. It was also found, as expected, 406 
that the molecules selected had a significant effect in terms of reduction of the S. mutans surface 407 
adhesion as a single microorganism, but it is very important to carry out complementary studies on 408 
multispecies biofilms models, also to identify through transcriptomic analysis if there are variations 409 
on the expression of adhesion genes dependent and independent of sucrose when treating bacteria 410 
with the selected molecules, as well as genes that participate in cell signaling during the biofilm 411 
development process. Similarly, an in vivo cariogenic model should be established in order to insight 412 
the anti-cariogenic capacity of these molecules.   413 
3. Materials and Methods  414 
3.1 Structure based virtual Screening 415 
3.1.1 Target proteins selection 416 
3D protein structures  for the virtual search were selected using the Ag I/II of S. mutans sequence 417 
AFR75221.1 (NCBI https://www.ncbi.nlm.nih.gov/) and the 3D SWISS-MODEL software 418 
(http://swissmodel.expasy.org/ ). 3D structures of two Ag I/II protein fragments 3IPK (PDB-ID) [21] 419 
and 3QE5 [20], were used for a sequence and protein structure similarity analysis using a BLAST-P 420 
(Protein Basic Local Alignment Search Tool - NCBI) and the FAT-CAT server (Flexible structure 421 
Alignment by Chaining Aligned fragment pairs allowing Twists) [70] to search for similar (rigid) 422 
protein structures, using similarities only with a P-value <0.05. Subsequently, for 3IPK and 3QE5 423 
proteins an analysis of binding sites “Pockets” using meta-servers MetaPocket 2.0 [49] and COACH 424 
[50] was carried out. 3D structures of the proteins were obtained in PDB format and edited in 425 
AutoDockTools 4.0 (http://mgltools.scripps.edu) [71]. Molecular docking of molecules with AgI/II 426 
protein fragments, was performed at the Texas Advanced Computing Center (TACC: Texas 427 
Advanced Computing Center; Austin, TX) using 3 libraries "ZINC (Lrg)" of ~ 642,759, Library "ZINC 428 
(Sm)" of ~ 46,702 molecules, and "ZINC Natural Cmpds (Large)" of 194,090 from the ZINC15 database 429 
[72], a total of ~ 883,551 molecules. 430 
3.1.2 Molecules selection:  431 
Two methodologies were used for molecules selection, one according to the molecular docking 432 
score and other according to the number of pockets in which molecules interacted, classification of 433 
molecules that interacted in most pockets was carried out using a script executed in the R-studio 434 
package (Version 1.0.156); ten molecules were arbitrarily selected from each methodology. An in silico 435 
analysis was performed using the QuikProp application (Version 3.2) from Schrödinger software [73], 436 
according to [74] with some modifications, in order to analyze pharmacokinetic profiles such as 437 
absorption, distribution, metabolism and excretion (ADME). Molecules that had more than two 438 
violations of the Lipinski’s Rules and that did not comply with more than two of the standard 439 
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physical-chemical parameters established by 95% of the known drugs, according to Schrödinger's 440 
QuikProp program repositories, were excluded. 441 
For computational toxicity prediction of the molecules, the Protox-II program was used [75], for 442 
acute toxicity, hepatotoxicity, cytotoxicity, carcinogenicity, mutagenicity and immunotoxicity. In 443 
addition, the molecules  lethal dose 50 (LD50) (mg/kg) was calculated and classified according to the 444 
Globally Harmonized System of Classification and Labeling of Chemicals (GHS). For this analysis, 445 
chlorhexidine was used as the reference drug, one of the most commonly prescribed antiseptic agents 446 
in dentistry; the experimental LD50 values of oral administration in mice of this drug were taken 447 
from the Pfizer chlorhexidine technical data sheet [76]. Molecules  above class 3 and without any 448 
probability of toxicity were selected. 449 
3.1.3 Molecule - protein interaction and solubility analysis  450 
ZINC19835187 (Database code Zinc15), ZINC19924906 and ZINC19924939, (ZI-187, ZI-906 and 451 
ZI-939, respectively) were selected and the H-bonding and hydrophobicity interactions between the 452 
molecules and the two protein fragments 3ipk - 3qe5 were identified [77] using Biovia Discovery 453 
Studio [78] and Chimera [79] softwares. The swissADME web server (http://www.swissadme.ch/) 454 
was used to predict water solubility characteristics of the molecules , using a consensus of three 455 
methods Log S (ESOL), Log S (Ali) and Log S (SILICOS- IT) [80]. 456 
3.2 In vitro assays  457 
Three molecules  were purchased (ZI-498 was not available for sale) from the MolPort company 458 
(https://www.molport.com). Stock solution of the molecules were diluted in 100% DMSO (dimethyl 459 
sulfoxide) at a concentration of 104 µM (ZI-187 (MW = 479.6) = 4796 µg/ml; ZI-906 (MW = 453.6) = 460 
4535, 6 µg/ml; ZI-939 (MW = 470.6) = 4075,9 µg/ml). 461 
3.2.1 Cytotoxicity and antimicrobial assays: 462 
Cytotoxic effects of ZI-187, ZI-906 and ZI-939 on periodontal ligament fibroblast cells (FLP) 463 
treated for 24 hours with each molecule was evaluated and analyzed by flow cytometry with 464 
propidium iodide (PI), using 100 µM of each molecules and DMSO 1 % . S. mutans - Lt11 (UB579 WT) 465 
[81] and C. albicans NCPF 3179 (NCPF, 1986) were cultured overnight in broth BHI BD® at 37 °C 466 
shaking at 250 RPM. The next day, S. mutans and C. albicans suspension in BHI broth (180 µl/well, 467 
OD600nm= 0.1) was seeded into 96-well plates (Costar, Cambridge, MA) with 20 µl of the molecules  468 
(concentrations of 1.000, 100, 10, µM. DMSO 10%), as a negative control (death) 0.2% Chlorhexidine 469 
digluconate (Farpag®) was used, while the corresponding broth without molecules were used as a 470 
positive growth control, as well as those treated with DMSO 10% [82]. After incubation for 24 hours 471 
at 37°C shaking at 250 RPM, the absorbance was measured in an Epoch™ Microplate 472 
spectrophotometer (BioTek®) (OD600nm), to evaluate cell growth and to establish the minimum 473 
inhibitory concentration (MIC) 474 
3.2.2 Adhesion assay:  475 
S. mutans-Lt11 (UB579 WT) was cultured in BHI broth (BD®) overnight at 37 °C shaking at 250 476 
RPMI. The culture medium was discarded and bacteria were washed with phosphate buffer solution 477 
(PBS 1X) by centrifugation at 3000 RPM for 10 minutes. Subsequently, bacterial suspension in PBS 478 
1X, OD600nm= 1 was measured using an Epoch™ Microplate spectrophotometer (BioTek®) and 180 µl 479 
were inoculated into a 96-well microplate (NEST®, Ref: 701001) with 20 µl of each molecule at 200, 480 
100, 50, 25, 12.5 µM and incubated for three hours at 37 °C shaking at 250 RPM [83]. S. mutans SpaP- 481 
strain (mutant for AgI/II also called SpaP) and S. mutans-Lt11 treated with DMSO 10% were used as 482 
control. Plate wells were washed with water and adherent cells were stained by adding 200 µL 0.05% 483 
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crystal violet for 15 min, washed and measured by absorbance at 600 nm after addition of 30% glacial 484 
acetic acid. 485 
3.2.3 Data analysis 486 
All experiments were performed in triplicate and reproduced three separate times. Cell viability 487 
percentages were reported as negative % PI ± SEM and analyzed by one-way ANOVA, followed by 488 
a Dunnett's multiple comparison test. In S. mutans and C. albicans growth and adhesion inhibition 489 
analysis, the OD data were normalized to percentages and analyzed using D'Agostino & Pearson 490 
omnibus and Shapiro-Wilk normality test; subsequently the nonparametric Kruskal–Wallis test with 491 
Dunnett's multiple comparisons against the controls S. mutans and C. albicans treated with DMSO 492 
10%. Finally, the half maximal inhibitory concentration (IC50) was calculated. GraphPad Prism 493 
version 6.0 (GraphPad Software, La Jolla California USA, www.graphpad.com) was used and values 494 
of P <0.05 were considered statistically significant.  495 
3.2.4 Scanning Electron Microscopy (SEM):  496 
Surface adhesion assays were performed on Thermo Scientific Nunc Lab-Tek and Lab Tek II Chamber 497 
Slides, using S. mutans - Lt11 untreated and treated with molecule ZI-187 (100 µM). After incubation 498 
for three hours at 37 °C shaking at 250 RPM, each sample was washed three times with PBS 1X , then 499 
the samples were fixed with 2,5% glutaraldehyde (0.1M PBS) for 24 hours at 4 °C. Finally, the slides 500 
were washed three times with distilled water and dehydrated by immersion in solutions of ascending 501 
concentrations of ethanol 70, 90 and 100% (10 minutes each) and dried overnight in a laminar flow 502 
cabinet. The samples were covered with gold and visualized using a FEI QUANTA-200TM scanning 503 
electron microscope with a variable range acceleration voltage of 1–30 KV. 504 
3.2.5 Molecular dynamics simulations (MD) 505 
MD simulations were carried out using the GROMACS 4.5.5 package [84]. Molecule ZI-187 was 506 
docked to the 3IPK protein pocket with the highest binding affinity (P1 by COACH predictor). The 507 
ZI-187/3IPK complex and the 3IPK protein in its APO state (reference state), were used as initial 508 
coordinates for MD simulations. Finally, both systems were subjected to a 300ns production stage, 509 
using a 2fs time step. The equilibrations and productions were carried out using a temperature of 510 
310K (36.85 °C) and a 1 bar pressure. Descriptors such as the RMSD (Root of the mean square 511 
deviation), the RMSF (Root of the mean square fluctuation) and hydrogen bonds present in the 512 
protein-ligand complex were followed with the tools contained g_rms, g_rmsf and g_hbond, 513 
respectively. 514 
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